Patents by Inventor Antonios Nikitidis

Antonios Nikitidis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DUAL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE DELTA & GAMMA
    Publication number: 20210246130
    Abstract: There are disclosed certain novel compounds (including pharmaceutically acceptable salts thereof), that inhibit phosphatidylinositol 3-kinase gamma (PI3K?) and phosphatidylinositol 3-kinase gamma (PI3K?) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Application
    Filed: February 11, 2021
    Publication date: August 12, 2021
    Inventors: Matthew PERRY, Christian TYRCHAN, Konstantinos KARABELAS, Antonios NIKITIDIS, Mickael MOGEMARK, Jens PETERSEN, Peter BOLD, Ulf BORJESSON
  • (S)-2-(1-cyclopropylethyl)-5-(4-methyl-2-((6-(2-oxopyrrolidin-1-yl)pyridin-2-yl)amino) thiazol-5-yl)-7-(methylsulfonyl)isoindolin-1-one as a phosphatidylinositol 3-kinase inhibitor
    Patent number: 10961236
    Abstract: Disclosed herein is the compound (S)-2-(1-cyclopropylethyl)-5-(4-methyl-2-((6-(2-oxopyrrolidin-1-yl)pyridin-2-yl)amino)thiazol-5-yl)-7-(methylsulfonyl)isoindolin-1-one of the following structure: and/or pharmaceutically acceptable salts and/or pharmaceutical compositions thereof, which inhibit phosphatidylinositol 3-kinase (PI3K) activity.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: March 30, 2021
    Assignee: AstraZeneca AB
    Inventors: Matthew Perry, Christian Tyrchan, Konstantinos Karabelas, Antonios Nikitidis, Mickael Mogemark, Jens Petersen, Peter Bold, Ulf Borjesson
  • 5-[2-(PYRIDIN-2-YLAMINO)-1,3-THIAZOL-5-YL]-2,3-DIHYDRO-1 H-ISOINDOL-1 -ONE DERIVATIVES AND THEIR USE AS DUAL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE DELTA & GAMMA
    Publication number: 20200308164
    Abstract: There are disclosed certain novel compounds (including pharmaceutically acceptable salts thereof), that inhibit phosphatidylinositol 3-kinase gamma (PI3K?) and phosphatidylinositol 3-kinase gamma (PI3K?) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Application
    Filed: September 21, 2017
    Publication date: October 1, 2020
    Applicant: AstraZeneca AB
    Inventors: Matthew PERRY, Christian TYRCHAN, Konstantinos KARABELAS, Antonios NIKITIDIS, Mickael MOGEMARK, Jens PETERSEN, Peter BOLD, Ulf BORJESSON
  • COMPOUNDS AND USES
    Publication number: 20170216283
    Abstract: There is provided compounds of formula I, wherein E1, E2, E3, E4, L1, Y1, Y2, Y3, Ra and z have meanings provided in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of leukotriene C4 synthase is desired and/or required, and particularly in the treatment of respiratory diseases and inflammation.
    Type: Application
    Filed: April 17, 2017
    Publication date: August 3, 2017
    Applicant: AstraZeneca AB
    Inventors: Robert Ronn, Carl Jonas Lindh, Erik Ringberg, Hanna Birgitta Ellinor Andersson, Peter Nilsson, Wesley Ralph Schaal, Magnus Munck af Rosenschöld, Antonios Nikitidis, Grigorios Nikitidis, Petra Johannesson, Christian Tyrchan
  • Compounds and uses
    Patent number: 9657001
    Abstract: There is provided compounds of formula I, wherein E1, E2, E3, E4, L1, Y1, Y2, Y3, Ra and z have meanings provided in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of leukotriene C4 synthase is desired and/or required, and particularly in the treatment of respiratory diseases and inflammation.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: May 23, 2017
    Assignee: ASTRAZENECA AB
    Inventors: Robert Ronn, Carl Jonas Lindh, Erik Ringberg, Hanna Birgitta Ellinor Andersson, Peter Nilsson, Wesley Ralph Schaal, Magnus Munck af Rosenschöld, Antonios Nikitidis, Grigorios Nikitidis, Petra Johannesson, Christian Tyrchan
  • COMPOUNDS AND USES
    Publication number: 20160326143
    Abstract: There is provided compounds of formula I, wherein E1, E2, E3, E4, L1, Y1, Y2, Y3, Ra and z have meanings provided in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of leukotriene C4 synthase is desired and/or required, and particularly in the treatment of respiratory diseases and inflammation.
    Type: Application
    Filed: May 4, 2016
    Publication date: November 10, 2016
    Applicant: AstraZeneca AB
    Inventors: Robert Ronn, Carl Jonas Lindh, Erik Ringberg, Hanna Birgitta Ellinor Andersson, Peter Nilsson, Wesley Ralph Schaal, Magnus Munck af Rosenschöld, Antonios Nikitidis, Grigorios Nikitidis, Petra Johannesson, Christian Tyrchan
  • 2-pyridone derivatives as neutrophil elastase inhibitors and their use
    Patent number: 8501784
    Abstract: There are provided novel compounds of formula (I), wherein R1, R2, R4, G1, G2, L, Y and n are as defined in the Specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of neutrophil elastase.
    Type: Grant
    Filed: October 14, 2011
    Date of Patent: August 6, 2013
    Assignee: Astrazeneca AB
    Inventors: Marjana Andersson, Peter Hansen, Hans Lonn, Antonios Nikitidis, Petter Sjölin
  • Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
    Patent number: 8466284
    Abstract: The invention provides certain novel compounds as listed in the specification and pharmaceutically acceptable salts thereof and particular Forms thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.
    Type: Grant
    Filed: November 5, 2008
    Date of Patent: June 18, 2013
    Assignee: Astra Zeneca AB
    Inventors: David Chapman, Martin Lindsjö, Hans Lönn, Michael Lundkvist, Magnus Munck AF Rosenschöld, Antonios Nikitidis, Debra Ainge, John Pavey
  • 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial
    Patent number: 8410114
    Abstract: The invention provides compounds of formula wherein R1, R3, R4, R5, R14, X and W are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.
    Type: Grant
    Filed: January 6, 2012
    Date of Patent: April 2, 2013
    Assignee: AstraZeneca AB
    Inventors: Peter Hansen, Marianne Ivarsson, Karolina Lawitz, Hans Lonn, Antonios Nikitidis, Asim Ray
  • 2-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL
    Publication number: 20120108610
    Abstract: The invention provides compounds of formula wherein R1, R3, R4, R5, R14, X and W are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.
    Type: Application
    Filed: January 6, 2012
    Publication date: May 3, 2012
    Applicant: ASTRAZENECA AB
    Inventors: Peter Hansen, Marianne Ivarsson, Karolina Lawitz, Hans Lonn, Antonios Nikitidis, Asim Ray
  • 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial
    Patent number: 8114881
    Abstract: The invention provides compounds of formula wherein R1, R3, R4, R5, R14, X and W are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.
    Type: Grant
    Filed: May 7, 2007
    Date of Patent: February 14, 2012
    Assignee: AstraZeneca AB
    Inventors: Peter Hansen, Marianne Ivarsson, Karolina Lawitz, Hans Lönn, Antonios Nikitidis, Asim Ray
  • 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE
    Publication number: 20120035157
    Abstract: There are provided novel compounds of formula (I), wherein R1, R2, R4, G1, G2, L, Y and n are as defined in the Specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of neutrophil elastase.
    Type: Application
    Filed: October 14, 2011
    Publication date: February 9, 2012
    Applicant: AstraZeneca AB
    Inventors: Marjana Andersson, Peter Hansen, Hans Lönn, Antonios Nikitidis, Petter Sjölin
  • 2-pyridone derivatives as neutrophil elastase inhibitors and their use
    Patent number: 8063073
    Abstract: There are provided novel compounds of formula (I), wherein R1, R2, R4, R5, G1, G2, L, Y and n are as defined in the Specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of neutrophil elastase.
    Type: Grant
    Filed: September 15, 2004
    Date of Patent: November 22, 2011
    Assignee: AstraZeneca AB
    Inventors: Peter Hansen, Hans Lönn, Antonios Nikitidis
  • Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
    Publication number: 20100280048
    Abstract: The invention provides certain novel 6-heteroaryl-5-methyl-3-oxo-4-[3(trifluoromethyl)phenyl]-3,4-dihydropyrazine-2-carboxamide derivatives and pharmaceutically acceptable salts thereof and particular Forms thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.
    Type: Application
    Filed: November 5, 2008
    Publication date: November 4, 2010
    Applicant: ASTRAZENECA R&D
    Inventors: Debra Ainge, David Chapman, Martin Lindsjo, Hans Lonn, Michael Lundkvist, Magnus Munck AF Rosen-Schold, Antonios Nikitidis, John Pavey
  • 2-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL
    Publication number: 20090209555
    Abstract: The invention provides compounds of formula wherein R1, R3, R4, R5, R14, X and W are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.
    Type: Application
    Filed: May 7, 2007
    Publication date: August 20, 2009
    Inventors: Peter Hansen, Marianne Ivarsson, Karolina Lawitz, Hans Lönn, Antonios Nikitidis, Asim Ray
  • 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE
    Publication number: 20090131483
    Abstract: The invention provides compounds of formula (I) wherein R1, R2, R3, R4, R5 and X are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.
    Type: Application
    Filed: March 14, 2006
    Publication date: May 21, 2009
    Inventors: Peter Hansen, Karolina Lawitz, Hans Lonn, Antonios Nikitidis
  • 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE
    Publication number: 20090105239
    Abstract: The invention provides compounds of formula wherein R1, R3, R4, R5, R6, R14, X, W and Z are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.
    Type: Application
    Filed: March 14, 2006
    Publication date: April 23, 2009
    Inventors: Thomas Brimert, Karolina Lawitz, Hans Lonn, Antonios Nikitidis, Asim Kumar Ray, Jenny Sandmark
  • Novel Quinoline-Carbaxamides as Jak3 Kinase Modulators
    Publication number: 20080153799
    Abstract: The present invention relates to novel compounds which are JAK3 Kinase inhibitors, methods for their preparation and pharmaceutical compositions comprising them.
    Type: Application
    Filed: February 7, 2005
    Publication date: June 26, 2008
    Applicant: ASTRAZENECA AB
    Inventors: David Laurent, Jorgen Gustafsson, Karolina Lawitz, Tesfaledet Mussie, Antonios Nikitidis
  • 2-Pyridone Derivatives As Neutrophil Elastase Inhibitors And Their Use
    Publication number: 20070203129
    Abstract: There are provided novel compounds of formula (I), wherein R1, R2, R4, R5, G1, G2, L, Y and n are as defined in the Specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of neutrophil elastase.
    Type: Application
    Filed: September 15, 2004
    Publication date: August 30, 2007
    Inventors: Marjana Andersson, Peter Hansen, Hans Lonn, Antonios Nikitidis, Petter Sjolin
  • 2-Pyridone derivatives as neutrophil elastase inhibitors and their use
    Publication number: 20070043036
    Abstract: There are provided novel compounds of formula (I), wherein R1, R2, R4, R5, G1, G2, L, Y and n are as defined in the Specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of neutrophil elastase.
    Type: Application
    Filed: September 15, 2004
    Publication date: February 22, 2007
    Inventors: Peter Hansen, Karolina Lawitz, Hans Lonn, Antonios Nikitidis